Zhou found that activating GITR on T cells within cholangiocarcinoma tumors increased their production of effector molecules and proliferation, suggesting that targeting GITR could be a potential immunotherapy for CCA patients (76). Here, TNFRSF18 is linked to cholangiocarcinoma.